This book offers an in indictment of the nation's drug enforcement approach focusing on the short-sighted policies that often deny patients suffering from chronic pain the medications they need. Pain Control and Drug Policy: A Time for Change focuses on America's national crisis in pain management caused by the widening divergence between the enormous contributions of opioids ("narcotics") to pain management in the clinical setting and the mistaken belief that they are dangerous, highly addictive drugs. After dissecting the strategy and tactics of the War on Drugs from medical, historical, legal, socioeconomic, and geopolitical perspectives, Guy Faguet MD indicts the 40-year-long War on Drugs for having failed to stem the supply of illicit drugs in America despite expenditures of half a trillion dollars, despite violating the basic human right to pain relief of tens of millions of American chronic pain sufferers, and despite fomenting organized crime, government corruption, racial injustice, and social disruption in both the United States and the producer countries. He concludes with a clarion call for the abandonment of the War on Drugs, disbanding the Drug Enforcement Administration, and encouraging Congress to repeal the Controlled Substances Act. As a clinical and research oncologist responsible for the chronic pain management of thousands of cancer patients over the course of his 30-year career, Dr. Faguet knows that the most effective and safest way to manage most cases of chronic pain is with opioids. All modern pain-management textbooks advocate "titration to effect" in cases where opioids help: that is, gradually increasing the dosage until either the pain is acceptably controlled or the side effects begin to outweigh the pain-relief benefits. Yet the vast majority of doctors don't practice what the medical textbooks teach and instead prescribe opioids very reluctantly and conservatively. As a result, only half of all chronic pain sufferers-and fewer than half of all cancer patients-get adequate pain relief from their doctors. Why do physicians radically undertreat pain that is susceptible to opioid analgesics? They fear that if they prescribe Schedule II opioids in accordance with the professional standards of pain management set by such medical bodies as the American Pain Society, they will be investigated by the DEA, stigmatized, prosecuted as criminals, stripped of their licenses, and sent to jail. Visit Guy B. Faguet, MD's website here: www.faguet.net.

Nervous System Drug Delivery: Principles and Practice helps users understand the nervous system physiology affecting drug delivery, the principles that underlie various drug delivery methods, and the appropriate application of drug delivery methods for drug- and disease-specific treatments. Researchers developing nervous system putative therapeutic agents will use this book to optimize drug delivery during preclinical assessment and to prepare for regulatory advancement of new agents. Clinicians will gain direct insights into pathophysiologic alterations that impact drug delivery and students and trainees will find this a critical resource for understanding and applying nervous system drug delivery techniques.

Translational Medicine in CNS Drug Development, Volume 29, is the first book of its kind to offer a comprehensive overview of the latest developments in translational medicine and biomarker techniques. With extensive coverage on all aspects of biomarkers and personalized medicine, and numerous chapters devoted to the best strategies for developing drugs that target specific disorders, this book presents an essential reference for researchers in neuroscience and pharmacology who need the most up-to-date techniques for the successful development of drugs to treat central nervous system disorders. Despite increases in the number of individuals suffering from CNS-related disorders, the development and approval of drugs for their treatment have been hampered by inefficiencies in advancing compounds from preclinical discovery to the clinic. However, in the past decades, game-changing strides have been made in our understanding of the pathophysiology of CNS disorders and the relationship of drug exposure in plasma and CNS to pharmacodynamic measures in both animals and humans.

The Core Model: A Collaborative Paradigm for the Pharmaceutical Industry and Global Health Care develops the innovative core model, an organizational research and design paradigm and economic theory that proposes a collaborative approach to resolving global health issues and improving the productivity of drug development. The model proposes that scientific collaboration does not occur in an unstructured manner, but actually takes place within a highly structured order where knowledge is transferred, integrated and finally translated into commercial products. An understanding of this model will help solve the global pharmaceutical industrys productivity problems and address important global health care and economic issues. This book is useful to researchers, advanced students, regulators, and management in pharmaceutical industries, as well as healthcare professionals, those working in health economics, and those interested in scientific innovation processes.

NETosis: Immunity, Pathogenesis and Therapeutics takes a focused approach to the clinical aspects of NETosis and drug development, bringing critical findings. Chapters introduce NETosis, consider mechanisms and antimicrobial strategies regulating NETosis, examine NETosis in neonates, explore the role of NETosis in autoimmunity, delve into NETosis and other diseases, and present therapeutic approaches for dysregulated NETosis. Since Brinkamm, et al, discovered an unrecognized neutrophil anti-microbial mechanism responsible for the extracellular killing of invading pathogens in 2004, the novel process in which nuclear chromatin de-condenses and DNA is ejected into the extra cellular environment, trapping and inactivating tissue pathogens has rapidly evolved.

This book sheds light on the major functions of microbial communities in aquaculture ecosystems, showing that by recycling nutrients, degrading organic matter and preventing disease outbreaks, a variety of microbes are truly beneficial to a wide range of aquaculture industries. It discusses how deteriorating environmental quality enables some microbial strains to trigger disease, describes the development of highly sustainable tools to improve water quality, and identifies crucial factors that endanger microbial homeostasis in aquaculture ecosystems. The book also covers post-antibiotic approaches for preventing and treating opportunistic microbial infections based on harnessing environmental and fish-associated microbial communities. Furthermore, it explores how manipulating and engineering these complex microbial communities using bio-agents such as probiotics, phages, natural nutritional additives, or with fine-tuned biofilters will open the door for new ways to develop a more sustainable and cost-effective aquaculture industry. Including an accessible presentation of modern high-throughput sequencing technology to identify host-microbial interactions in aquaculture ecosystems, this book is a valuable resource for scientists, aquaculture and fishery experts, sustainability enthusiasts and scholars in the areas of biology and marine agriculture.

AHFS Drug Information (R) 2022 contains the most dependable drug information available-all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses. With expanded and revised content supported by more than 97,000 references and incorporating the advice of numerous subject matter experts, AHFS DI helps you protect your patients and your practice. Updates in the new edition: The latest information on COVID-19 vaccines and COVID-19 monoclonal antibodies available under FDA Emergency Use Authorizations (EUAs), including clinical considerations from the US Centers for Disease Control and Prevention (CDC), and National Institutes of Health (NIH). Information on patient selection and appropriate use of corticosteroids in the management of COVID-19 based on recent guidelines from NIH and the World Health Organization (WHO). Contemporary issues such as anticoagulant reversal strategies and use of direct oral anticoagulants versus warfarin for treatment of venous thromboembolism or atrial fibrillation. Current best practices such as reversal of neuromuscular blocking agents for prevention of postoperative residual neuromuscular blockade. Newly published information on breakthrough oncology drugs approved as part of the FDA's accelerated approval program. Expanded content on off-label uses, real-world data, and long-term clinical data. Updated information on pharmacogenomic considerations based on recommendations from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Addition of 51 new molecular entities (NMEs) or new therapeutic biological products approved since January 2021.

Microencapsulations may be found in a number of fields like medicine, drug delivery, biosensing, agriculture, catalysis, intelligent microstructures and in many consumer goods. This new edition of Microencapsulation revises chapters to address the newest innovations in fields and adds three new chapters on the uses of microencapsulations in medicine, agriculture, and consumer products.

Nutritional Epigenomics offers a comprehensive overview of nutritional epigenomics as a mode of study, along with nutrition's role in the epigenomic regulation of disease, health and developmental processes. Here, an expert team of international contributors introduces readers to nutritional epigenomic regulators of gene expression, our diet's role in epigenomic regulation of disease and disease inheritance, caloric restriction and exercise as they relate to recent epigenomic findings, and the influence of nutritional epigenomics over circadian rhythms, aging and longevity, and fetal health and development, among other processes. Disease specific chapters address metabolic disease (obesity and diabetes), cancer, and neurodegeneration, among other disorders. Diet-gut microbiome interactions in the epigenomic regulation of disease are also discussed, as is the role of micronutrients and milk miRNAs in epigenetic regulation. Finally, chapter authors examine ongoing discussions of race and ethnicity in the social-epigenomic regulation of health and disease.

For more than 40 years ASHP has published the most trusted resource for injectable drug information. Our new ASHP (R) Injectable Drug Information now delivers the same high-quality content that you can expect from ASHP with even more of the information you need to make decisive patient care decisions. The 2023 edition of the industry's go-to guide is newly updated with the latest information, the full list of the AHFS (R) Pharmacologic-Therapeutic Classification (c) system, multiple new monographs, and nearly 200 new references for a total of over 24,000 total compatibility pairs. ASHP (R) Injectable Drug Information (TM) 2023 features more than 400 monographs, including: Brexanolone Cefiderocol sulfate tosylate Oritavancin Oliceridine fumarate Remdesivir Remimazolam besylate Sildenafil citrate

The Side Effects of Drugs Annual was first published in 1977. It has been continually published since then, as a yearly update to the voluminous encyclopedia Meyler's Side Effects of Drugs. Each new Annual continues to provide clinicians and medical investigators with a reliable and critical yearly survey of new data and trends in the area of Adverse Drug Reactions and Interactions. An international team of specialists has contributed to the Annuals by selecting critically from each year's writing all that is truly new and informative, by critically interpreting it, and by pointing to whatever is misleading.
*Provides a critical yearly survey of new data and trends
*Includes an essay that describes the modern approach to classifying adverse drug reactions
*Special reviews in this Annual include, among other topics: Antipsychotic drugs and now-onset diabetes mellitus, Treating asthma during pregnancy, and MMR vaccine and autism

This is a review of clinical adverse effects on the human immune system that may occur following drug treatments and chemcical exposures. Current and prospective models and assays that can be used to predict these adverse effects in animal toxicity studies or in human beings are described.

The aim of this book is not only to introduce readers with a broad spectrum of biological actions of the NOP receptor, but also to feature a detailed look at the N/OFQ-NOP receptor system, medicinal chemistry, pharmacology, and clinical data of NOP-targeted ligands. This special volume book - for the first time focusing on the NOP receptor - is designed to serve as a useful reference, stimulate more research on the N/OFQ-NOP receptor system, and lead to more development of NOP-related ligands for several therapeutic applications.

Postmortem Toxicology addresses the various aspects of the practice of forensic postmortem toxicology from a viewpoint of elements which must be taken into consideration for proper interpretation of the toxicological result, not in a vacuum but in a more holistic and global sense. The volume examines pre-analytical factors, storage containers/conditions, prior medical interventions and therapy, along with information from the scene investigation and anatomical findings. This reference also provides explanation of the complicating conditions for the interpretation of the toxicological results due to postmortem decomposition, embalming artifacts and the postmortem redistribution of drugs. Tolerance is also discussed as an aid to interpreting results from a habitual/chronic user of medications and/or drugs of abuse. The book is geared towards the current practitioner; however, it is written to be used as a valuable reference for a graduate or post-graduate level courses in forensic toxicology or forensic pathology.